Certara Earns Great Place to Work Certification™ for Fourth Consecutive Year Blog Post
Certara wins Great Place to Work Certification, with 85% of employees praising workplace culture, innovation, and collaboration.
A Quantitative Systems Pharmacology Model to Investigate the Crucial Role of Epithelial Damage in the Pathogenesis of Inflammatory Bowel Disease Blog Post
In inflammatory bowel disease (IBD) patients, there is an imbalance between pro- and anti-inflammatory cytokines. When the epithelium is damaged, overproduction of pro-inflammatory cytokines causes inflammation, damaging the epithelium further,...
Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance Blog Post
With the release of the draft ICH M15 guidance, MIDD is no longer optional – it’s becoming a global regulatory expectation. Learn all you need to know in this blog.
Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis Blog Post
[event_date_range]
EACPT 2025 CONGRESS Blog Post
[event_date_range] – [acf field="event_location"] – Booth [acf field="event_booth"]
What are the most common in vitro drug-drug interaction study gaps? Blog Post
Certara drug interaction science experts share data and experimental design gaps commonly found in in vitro drug-drug interaction studies.
On-Demand Webinar: Streamlining Population PK Modeling with Phoenix NLME and Pirana Blog Post
Learn more about Phoenix™ NLME Phoenix NLME offers unparalleled flexibility and power for PK/PD analyses, meeting all scientific and technical requirements for global regulatory submissions. Learn moreBook a demo You... Transform Your PK/PD Workflow with AI and the Cloud Blog Post
[event_date_range]
